Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178247 | 1.00 | GSR (0.34) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL3994460 | 0.93 | — | — | |
| SCHEMBL10784463 | 0.80 | GSR (0.35) | GSRRNPEPCPB2NFKB1FOLH1 | |
| SCHEMBL9853666 | 0.80 | MAPT (0.38) | — | |
| SCHEMBL1308490 | 0.79 | GSR (0.32) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL451174 | 0.78 | GSR (0.39) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL9853678 | 0.78 | MAPT (0.41) | — | |
| SCHEMBL19100559 | 0.78 | GSR (0.39) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL451173 | 0.78 | GSR (0.39) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL3854190 | 0.78 | EPHX1 (0.36) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101595103-A | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | CN | claimed |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA (SE) | 2009-10-29 | — | — | US | claimed |
| CN-101563340-A | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | CN | claimed |
| US-20090233926-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (SE) | 2009-09-17 | — | — | US | claimed |
| EP-2064203-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | claimed |
| WO-2008032072-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| US-8445224-B2 | Method for assaying FTO (2-oxoglutarate dependent oxygenase) activity | ISIS INNOVATION LIMITED (GB) | 2013-05-21 | — | — | US | disclosed |
| EP-2171446-B1 | A METHOD FOR ASSAYING FTO (2-OXOGLUTARATE DEPENDENT OXYGENASE) ACTIVITY | ISIS INNOVATION (GB) | 2013-04-24 | — | — | EP | disclosed |
| US-20110166208-A1 | Nucleotide and Amino Acid Sequences for Calmodulin Protein Methyltransferase | UNIVERSITY OF KENTUCKY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100216832-A1 | Method for Assaying FTO (2-Oxoglutarate Dependent Oxygenase) Activity | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-2171446-A1 | A METHOD FOR ASSAYING FTO (2-OXOGLUTARATE DEPENDENT OXYGENASE) ACTIVITY | ISIS Innovation Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (GB) | 2010-01-28 | — | — | US | disclosed |
| EP-2064203-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008155556-A1 | A METHOD FOR ASSAYING FTO (2-OXOGLUTARATE DEPENDENT OXYGENASE) ACTIVITY | ISIS INNOVATION LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008032072-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007066103-A1 | PYRIMIDINE DERIVATIVES AS CLASS I PI3K INHIBITOR | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| EP-0688314-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021604-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233926-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | GSR 3667/4885RNPEP 3940/4885GNAI3 2400/4885 |
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MTOR, PIK3CA, PIK3CD | GSR 4231/4885RNPEP 3460/4885GNAI3 3029/4885 |
| US-20100216832-A1 | Method for Assaying FTO (2-Oxoglutarate Dependent Oxygenase) Activity | FTO, ALKBH3, TET2 | GSR 1047/4885RNPEP 1186/4885GNAI3 1169/4885 |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | TYMP, DPYD, TYMS | GSR 1044/4885RNPEP 1771/4885GNAI3 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.